bluebird bio, Inc.
BCMA chimeric antigen receptors
Last updated:
Abstract:
The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
Status:
Grant
Type:
Utility
Filling date:
3 Jul 2019
Issue date:
21 Apr 2020